artenimol has been researched along with Benign Neoplasms in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 10 (37.04) | 24.3611 |
| 2020's | 17 (62.96) | 2.80 |
| Authors | Studies |
|---|---|
| Arellano, ML; Boggon, TJ; Brat, DJ; Chen, GZ; Chen, J; Chen, PR; DeBerardinis, RJ; Elf, S; Fan, J; Gu, TL; He, C; Hitosugi, T; Hurwitz, SJ; Ji, Q; Jiang, L; Kang, HB; Kang, S; Khoury, HJ; Khuri, FR; Lee, BH; Lei, Q; Li, Y; Lin, R; Lonial, S; Mao, H; Mitsche, M; Seo, JH; Shan, C; Sudderth, J; Tucker, M; Wang, D; Wu, S; Xie, J; Ye, K; Zhang, L; Zhang, S; Zhou, L | 1 |
| Bai, L; Gong, J; Jin, Y; Peng, T; Shi, J; Tong, R; Wei, X; Zhou, Y | 1 |
| Das, D; Hong, J | 1 |
| Liu, Y; Xu, Z; Zhao, SJ | 1 |
| Emami, SA; Taleghani, A; Tayarani-Najaran, Z | 1 |
| Amewu, RK; Burrell-Saward, H; Chadwick, J; Hussain, A; Janneh, O; Miguel, C; O'Neill, PM; Panda, S; Rinki, R; Vivas, L; Ward, SA | 1 |
| Chan, C; Duan, X; Han, W; Li, Y; Lin, W; Ni, K | 1 |
| Cui, B; Feng, X; Han, L; Li, W; Li, Y; Pei, Q; Xie, Z; Zhang, H; Zhu, W | 1 |
| Chen, X; Han, N; Li, LG; Li, QR; Li, TF; Peng, XC; Wang, MF; Wen, Y; Xu, HZ; Xu, X; Yang, XX; Yu, TT | 1 |
| Duan, D; Li, Y; Ren, G; Wang, G; Wang, R; Zhang, G; Zhang, Q; Zhang, S; Zhao, Y; Zuo, H | 1 |
| Cao, W; Chen, X; Ding, F; Dong, T; Wang, P | 1 |
| Chen, L; Pan, B; Xu, D; Xu, Z | 1 |
| Che, S; Fahad, A; Gao, X; Guo, Z; Jin, Z; Li, Y; Lu, J; Wei, Y; Xie, W; Yu, J; Zhang, Z; Zhao, L | 1 |
| Bing, J; Chen, M; Gao, S; Ge, M; Pu, Y; Shen, Y; Shi, J; Wu, W; Zhou, B; Zhou, M; Zhu, Y | 1 |
| Gong, S; Hu, Y; Lu, M; Luo, Y; Ma, XN; Tian, J; Wu, Y; Xu, Z; Yu, BY; Yu, XA; Zhang, Y | 1 |
| Abubakar, IB; Alhassan, AM; Bunza, AM; Etti, IC; Malami, I; Muhammad, A; Waziri, PM; Yunusa, A | 1 |
| Du, M; Gao, P; Gu, L; Liu, Q; Liu, S; Shen, S; Wang, J | 1 |
| Gao, J; Li, G; Ma, F; Wang, X | 1 |
| Che, S; Chi, Y; Gao, F; Gu, Z; Guo, Z; Lu, J; Takuya, N; Xu, J; Xu, W; Yu, J; Zhang, J; Zhao, L | 1 |
| Buettner, GR; Du, J; Goswami, PC; Kalen, AL; Modi, MM; Pigge, FC; Sarsour, EH; Schultz, MK; Varmazyad, M; Wagner, B | 1 |
| Chen, W; Chen, Y; Dai, X; Lu, J; Mo, S; Zhang, Q; Zhang, X | 1 |
| Benthani, FA; Bian, ZX; Chen, GQ; Jiang, X; Liang, D; Wu, J | 1 |
| Chen, SS; Hu, W; Lou, XE; Wang, Z; Zhou, HJ | 1 |
| Guo, C; Liang, Z; Mou, Y; Tian, Y; Xu, H | 1 |
| Cao, P; Leng, D; Li, X; Li, Y; Liu, L; Zhang, Z | 1 |
| Li, A; Lou, XE; Wang, Z; Zhang, JL; Zhou, HJ | 1 |
| Ba, Q; Chen, T; Chu, R; Duan, J; Hao, M; Li, J; Wang, H; Yang, X; Yin, J; Zhou, N | 1 |
6 review(s) available for artenimol and Benign Neoplasms
| Article | Year |
|---|---|
6-Phosphogluconate dehydrogenase links oxidative PPP, lipogenesis and tumour growth by inhibiting LKB1-AMPK signalling.
Topics: AMP-Activated Protein Kinase Kinases; AMP-Activated Protein Kinases; Humans; Lipogenesis; Neoplasms; Oxidative Stress; Pentose Phosphate Pathway; Phosphogluconate Dehydrogenase; Protein Serine-Threonine Kinases; Ribulosephosphates; Signal Transduction | 2015 |
Inhibitors of phosphodiesterase as cancer therapeutics.
Topics: Animals; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Humans; Molecular Structure; Neoplasms; Phosphodiesterase Inhibitors; Phosphoric Diester Hydrolases; Structure-Activity Relationship | 2018 |
Recent advancements of 4-aminoquinazoline derivatives as kinase inhibitors and their applications in medicinal chemistry.
Topics: Animals; Antineoplastic Agents; Chemistry Techniques, Synthetic; Humans; Neoplasms; Protein Kinase Inhibitors; Quinazolines | 2019 |
1,2,3-Triazole-containing hybrids as potential anticancer agents: Current developments, action mechanisms and structure-activity relationships.
Topics: Antineoplastic Agents; Humans; Molecular Structure; Neoplasms; Structure-Activity Relationship; Triazoles | 2019 |
Artemisia: a promising plant for the treatment of cancer.
Topics: Animals; Antineoplastic Agents, Phytogenic; Artemisia; Cell Proliferation; Humans; Molecular Structure; Neoplasms; Neoplasms, Experimental; Plant Extracts; Plants, Medicinal | 2020 |
Dihydroartemisinin: A Potential Natural Anticancer Drug.
Topics: Animals; Antineoplastic Agents, Phytogenic; Artemisia; Artemisinins; Drug Delivery Systems; Humans; Neoplasms; Phytotherapy | 2021 |
21 other study(ies) available for artenimol and Benign Neoplasms
| Article | Year |
|---|---|
Synthesis and evaluation of the antimalarial, anticancer, and caspase 3 activities of tetraoxane dimers.
Topics: Antimalarials; Antineoplastic Agents; Caspase 3; Cell Line, Tumor; Dimerization; Humans; Malaria, Falciparum; Neoplasms; Plasmodium falciparum; Tetraoxanes | 2013 |
Co-delivery of dihydroartemisinin and pyropheophorbide-iron elicits ferroptosis to potentiate cancer immunotherapy.
Topics: Artemisinins; Cell Line, Tumor; Ferroptosis; Immunotherapy; Iron; Neoplasms | 2022 |
A redox-responsive dihydroartemisinin dimeric nanoprodrug for enhanced antitumor activity.
Topics: Animals; Antineoplastic Agents; Apoptosis; Artemisinins; Cell Line, Tumor; Dimerization; Drug Liberation; Glycolysis; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Mice; Nanoparticles; Neoplasms; Oxidation-Reduction; Phosphatidylinositol 3-Kinases; Prodrugs; Signal Transduction; Transplantation, Heterologous | 2021 |
A nanoreactor boosts chemodynamic therapy and ferroptosis for synergistic cancer therapy using molecular amplifier dihydroartemisinin.
Topics: Artemisinins; Cell Line, Tumor; Ferroptosis; Glutathione; Humans; Hydrogen Peroxide; Iron; Nanomedicine; Neoplasms; Reactive Oxygen Species; Tumor Microenvironment | 2022 |
Construction of reduction-sensitive heterodimer prodrugs of doxorubicin and dihydroartemisinin self-assembled nanoparticles with antitumor activity.
Topics: Animals; Artemisinins; Cell Line, Tumor; Disulfides; Doxorubicin; Drug Delivery Systems; Mice; Nanoparticles; Neoplasms; Prodrugs | 2022 |
The anti-breast cancer potential of dihydroartemisinin-isatin hybrids with hydrogen bond donors at C-3 position of isatin moiety.
Topics: Antineoplastic Agents; Hydrogen Bonding; Isatin; Molecular Structure; Neoplasms; Structure-Activity Relationship | 2023 |
Design, synthesis, and in vitro cytotoxicity evaluation of novel dihydroartemisinin-isatin hybrids tethered via different length of esters as potential anti-breast cancer agents.
Topics: Antineoplastic Agents; Artemisinins; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Isatin; Molecular Structure; Neoplasms; Structure-Activity Relationship | 2023 |
Acidity-Triggered Charge-Convertible Conjugated Polymer for Dihydroartemisinin Delivery and Tumor-Specific Chemo-Photothermal Therapy.
Topics: Humans; Hyperthermia, Induced; Neoplasms; Phototherapy; Photothermal Therapy; Polymers; Tumor Microenvironment | 2023 |
Biomimetic inducer enabled dual ferroptosis of tumor and M2-type macrophages for enhanced tumor immunotherapy.
Topics: Biomimetics; Cell Line, Tumor; Ferroptosis; Glutathione; Humans; Immunosuppressive Agents; Immunotherapy; Macrophages; Neoplasms; Tumor Microenvironment | 2023 |
A cancer-specific activatable theranostic nanodrug for enhanced therapeutic efficacy via amplification of oxidative stress.
Topics: Animals; Artemisinins; Buthionine Sulfoximine; Drug Carriers; Female; Glutathione; Hep G2 Cells; Humans; Liposomes; Mice; Mice, Inbred BALB C; Mice, Nude; Nanoparticles; Neoplasms; Oxidation-Reduction; Oxidative Stress; Precision Medicine; Reactive Oxygen Species; Transferrin | 2020 |
Dihydroartemisinin as a potential drug candidate for cancer therapy: a structural-based virtual screening for multitarget profiling.
Topics: Artemisinins; Early Detection of Cancer; Humans; Molecular Docking Simulation; Neoplasms | 2022 |
Development of GLUT1-targeting alkyl glucoside-modified dihydroartemisinin liposomes for cancer therapy.
Topics: Artemisinins; Cell Line, Tumor; Glucose Transporter Type 1; Glucosides; Humans; Liposomes; Neoplasms | 2020 |
Combination of dihydroartemisinin and resveratrol effectively inhibits cancer cell migration
Topics: Antineoplastic Agents; Artemisinins; Biomarkers, Tumor; Cell Line, Tumor; Cell Movement; Drug Synergism; Drug Therapy, Combination; GTPase-Activating Proteins; Humans; Neoplasms; Resveratrol; Tumor Protein, Translationally-Controlled 1; Tumor Suppressor Proteins | 2020 |
Dihydroartemisinin loaded layered double hydroxide nanocomposites for tumor specific photothermal-chemodynamic therapy.
Topics: Animals; Antineoplastic Agents; Artemisinins; Cell Line, Tumor; Female; Hydroxides; Mice; Mice, Inbred BALB C; Nanocomposites; Neoplasms; Photosensitizing Agents; Photothermal Therapy; Xenograft Model Antitumor Assays | 2020 |
N-alkyl triphenylvinylpyridinium conjugated dihydroartemisinin perturbs mitochondrial functions resulting in enhanced cancer versus normal cell toxicity.
Topics: Antimalarials; Apoptosis; Artemisinins; Cell Line, Tumor; Cell Proliferation; Humans; Mitochondria; Neoplasms | 2021 |
Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis.
Topics: Animals; Antineoplastic Agents; Artemisinins; Autophagy; Cell Line, Tumor; Female; Ferroptosis; Homeostasis; Humans; Iron; Iron-Regulatory Proteins; Lysosomes; Mice, Nude; Neoplasms; Response Elements | 2020 |
p8 attenuates the apoptosis induced by dihydroartemisinin in cancer cells through promoting autophagy.
Topics: Antimalarials; Apoptosis; Artemisinins; Autophagy; Basic Helix-Loop-Helix Transcription Factors; Cell Line, Tumor; Endoplasmic Reticulum Stress; HeLa Cells; Humans; Neoplasm Proteins; Neoplasms; Signal Transduction | 2015 |
Design, Synthesis and Cytotoxicity of Novel Dihydroartemisinin-Coumarin Hybrids via Click Chemistry.
Topics: Antigens, Neoplasm; Artemisinins; Carbonic Anhydrase IX; Cell Proliferation; Click Chemistry; Coumarins; Drug Design; Enzyme Inhibitors; HCT116 Cells; Humans; Magnetic Resonance Spectroscopy; Neoplasms | 2016 |
[Progress on anti-tumor molecular mechanisms of dihydroartemisinin].
Topics: Antigens, CD; Antineoplastic Agents; Apoptosis; Artemisinins; Endocytosis; Free Radicals; Humans; Iron; Neoplasms; Oxidative Stress; Receptors, Transferrin | 2016 |
Dihydroartemisinin improves the efficiency of chemotherapeutics in lung carcinomas in vivo and inhibits murine Lewis lung carcinoma cell line growth in vitro.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Artemisinins; Carcinoma, Lewis Lung; Cell Cycle; Cell Proliferation; Cell Survival; Cisplatin; Cyclophosphamide; Drug Screening Assays, Antitumor; Female; Humans; Mice; Mice, Inbred BALB C; Mice, Inbred C57BL; Neoplasm Metastasis; Neoplasms; Random Allocation; Tumor Burden; Vascular Endothelial Growth Factor Receptor-2; Xenograft Model Antitumor Assays | 2010 |
Dihydroartemisinin exerts its anticancer activity through depleting cellular iron via transferrin receptor-1.
Topics: Antigens, CD; Antineoplastic Agents; Artemisinins; Cell Line, Tumor; Cell Membrane; Down-Regulation; Gene Expression Regulation; Gene Expression Regulation, Neoplastic; Homeostasis; Humans; Intracellular Space; Iron; Membrane Microdomains; Neoplasms; Receptors, Transferrin; Transferrin | 2012 |